• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Egetis Therapeutics

5.67 SEK

-4.38 %

Less than 1K followers

EGTX

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
-4.38 %
-6.59 %
+13.51 %
+6.18 %
+19.12 %
+40.00 %
+14.89 %
+6.73 %
-59.02 %

Egetis Therapeutics is a pharmaceutical company focused on developing innovative treatments for rare diseases. The company researches new therapies that can improve patient outcomes and quality of life. The business has a global presence and serves customers worldwide. Egetis Therapeutics was founded in 2006 and is headquartered in Stockholm, Sweden.

Read more
Market cap
2.78B SEK
Turnover
3.93M SEK
Revenue
62.4M
EBIT %
-544.71 %
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
EPS and dividend
Financial calendar
21.8
2026

Interim report Q2'26

6.11
2026

Interim report Q3'26

All
Webcasts
Press releases
ShowingAll content types

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Regulatory press release5/29/2026, 8:00 AM

Change in the number of shares and votes in Egetis Therapeutics

Egetis Therapeutics
Press release5/19/2026, 12:00 PM

Egetis to present healthcare resource drivers and cost in MCT8 deficiency at ISPOR 2026

Egetis Therapeutics
Press release5/13/2026, 2:45 PM

Exercise of options under employee stock option program and notification of insider trading

Egetis Therapeutics

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Press release5/7/2026, 8:00 AM

Egetis Therapeutics to Participate in Leading International Medical Conferences in 2026

Egetis Therapeutics
Press release5/5/2026, 6:00 AM

Egetis Announces Grant of Patent for MCT8 Deficiency Composition in the U.S.

Egetis Therapeutics
Press release4/30/2026, 10:30 AM

Egetis Therapeutics to Participate in Pediatric Endocrine Society Annual Meeting 2026

Egetis Therapeutics
Regulatory press release4/30/2026, 7:05 AM

Change in the number of shares and votes in Egetis Therapeutics

Egetis Therapeutics
Egetis Therapeutics, Audiocast, Q1'26
Webcast4/29/2026, 8:00 AM

Egetis Therapeutics, Audiocast, Q1'26

Egetis Therapeutics
Regulatory press release4/29/2026, 5:00 AM

Interim report Q1 2026

Egetis Therapeutics
Press release4/24/2026, 9:00 AM

Invitation to Presentation of Egetis’ First Quarter 2026 Report on April 29, 2026

Egetis Therapeutics
Regulatory press release4/21/2026, 8:57 PM

Egetis Therapeutics has successfully carried out a directed share issue amounting to SEK 350 million (approximately USD 38 million)

Egetis Therapeutics
Regulatory press release4/21/2026, 3:31 PM

Egetis Therapeutics announces the intention to carry out a directed share issue of approximately SEK 350 million (approximately USD 38 million)

Egetis Therapeutics
Regulatory press release4/14/2026, 1:45 PM

Bulletin from Egetis Therapeutics’ Annual General Meeting 2026

Egetis Therapeutics
Press release4/9/2026, 5:00 AM

Egetis Appoints Tiago Nunes as Chief Medical Officer

Egetis Therapeutics
Press release4/8/2026, 11:20 AM

Egetis Receives Conditional FDA Acceptance of Proprietary Name Emcitate®

Egetis Therapeutics
Regulatory press release3/27/2026, 3:42 PM

Egetis Announces FDA Acceptance and Priority Review of NDA for Emcitate® (tiratricol) for MCT8 Deficiency

Egetis Therapeutics
Regulatory press release3/24/2026, 2:05 PM

Egetis Therapeutics’ Annual Report 2025 published

Egetis Therapeutics
Regulatory press release3/12/2026, 11:02 AM

NOTICE OF ANNUAL GENERAL MEETING IN EGETIS THERAPEUTICS AB (PUBL)

Egetis Therapeutics
Press release3/9/2026, 6:00 AM

Egetis Receives Notice of Allowance for MCT8 Deficiency Composition Patent in the U.S.

Egetis Therapeutics
Press release3/5/2026, 9:56 AM

Redeye: Egetis Therapeutics (Q4 review): US approval on the horizon

Egetis Therapeutics